BioMedNewsBreaks Archive - Page 27 of 275

FridayJan 30, 2026 10:45 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) Highlights Board Appointments and AVERSA Fentanyl Milestones From Annual Meeting

Nutriband (NASDAQ: NTRB) (NASDAQ: NTRBW) provided shareholders with an update following its 2026 Annual Shareholders Meeting held Jan. 24, 2026, in Orlando, Florida, highlighting the appointment of two new directors, Alessandro Puddu and Viorica Carlig, and outlining key progress in the development of AVERSA(TM) FENTANYL. During 2025, the company strengthened its exclusive partnership with Kindeva, completed commercial manufacturing scale-up, expanded global patent protection including new U.S. and Macao patents, engaged with the U.S. Food and Drug Administration through a Type C meeting, and advanced branding initiatives for AVERSA(TM) FENTANYL. Looking ahead to 2026, Nutriband plans to advance toward an NDA filing by extending patent protection potentially to 2046, manufacturing…

ThursdayJan 29, 2026 12:38 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM)

Cutaneous T-cell lymphoma, or CTCL, is recognized by clinicians as one of the most difficult cancers to diagnose accurately in its early stages. A recent article discussed Soligenix’s (NASDAQ: SNGX) efforts to develop therapies aimed at addressing critical gaps in rare disease treatment, including CTCL. The publication reads, “Within a challenging diagnostic and treatment landscape, Soligenix is advancing a novel therapeutic approach for CTCL through its development of HyBryte(TM), also known as synthetic hypericin. HyBryte is a visible light-activated photodynamic therapy designed for the treatment of early-stage CTCL. Unlike traditional ultraviolet-based phototherapies, which can carry long-term safety risks with cumulative exposure, HyBryte is activated by visible light in the red-yellow spectrum,…

ThursdayJan 29, 2026 9:00 am

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands U.S. Clinical Site Network for Phase III GelrinC(R) Trial

Regentis Biomaterials (NYSE American: RGNT) announced the expansion of its U.S. clinical site network to support its ongoing pivotal Phase III study of GelrinC(R) for knee cartilage repair and future clinical programs. The expanded network includes leading academic and orthopedic institutions across the United States, including NYU Langone Orthopedic & Sports Medicine, The Ohio State University Wexner Medical Center, University of Cincinnati Medical Center, Loyola Medicine Orthopedic, Tulane University School of Medicine, UNC Orthopedics and Rush University Medical Center, with the company aiming to accelerate patient enrollment, strengthen clinical execution and support future commercialization efforts. To view the full press…

TuesdayJan 27, 2026 10:10 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287

CNS Pharmaceuticals (NASDAQ: CNSP) released a Letter to Shareholders from newly appointed President and Chief Executive Officer Rami Levin outlining a comprehensive strategic evaluation of the Company’s pipeline, operations and capital allocation priorities. The letter emphasizes a disciplined, patient-first approach centered on optimizing TPI 287 as the Company’s lead asset, refining its development and regulatory pathway, prioritizing high-value indications, and aligning resources toward milestone-driven execution, while also selectively evaluating pipeline expansion opportunities to support long-term shareholder value creation. To view the full press release, visit https://ibn.fm/mEy9f About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline…

FridayJan 23, 2026 9:10 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Engages IBN for Corporate Communications Support

Earth Science Tech (OTC: ETST), a strategic holding company advancing a portfolio of operating businesses within regulated healthcare markets, announced that it has engaged InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, to assist with its corporate communications strategy, reflecting the company’s focus on execution, compliance and disciplined scaling across licensed pharmaceutical compounding, digital health and telemedicine platforms, specialty healthcare services and complementary assets, with hands-on operational oversight through wholly owned and majority-owned subsidiaries aimed at building sustainable revenue streams and long-term shareholder value. To view the full press release, visit https://ibn.fm/5qFTn About Earth Science Tech, Inc. Earth Science…

ThursdayJan 22, 2026 9:25 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Appoints Bryan Humbarger as Chief Commercial Officer

HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care through actionable cardiac insights, announced the appointment of Bryan Humbarger as chief commercial officer, effective Jan. 22, 2026. In the newly created role, Humbarger will lead commercial strategy and execution across key growth initiatives, including the limited launch of the recently cleared HeartBeam System for arrhythmia assessment, heart attack detection indication and a 12-lead ECG extended wear patch monitor, while expanding outreach to cardiology partners to validate real-world performance and establish reference sites for broader adoption. To view the full press release, visit https://ibn.fm/9YzeT About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical…

WednesdayJan 21, 2026 1:30 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc.’s (OTLC) Deciparticle(TM) Platform Expands Possibilities in Immunology and Oncology

Oncotelic Therapeutics (OTCQB: OTLC) is rapidly emerging in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. “Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new data at the 2025 San Antonio Breast Cancer Symposium (‘SABCS’), highlighting that its Deciparticle(TM) platform can package even the toughest, water-resistant drugs into smaller, uniform nanoparticles that are small enough for effective and safe intravenous use,” reads a recent article. “The platform shows high-level compatibility across different therapeutic categories. All five main macrolide mTOR inhibitors, including temsirolimus, sirolimus, ridaforolimus, Everolimus (Afinitor(R)), and umirolimus, formed stable,…

TuesdayJan 20, 2026 12:53 pm

BioMedNewsBreaks — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) to Participate In DealFlow Discovery Conference

Lixte Biotechnology Holdings (NASDAQ: LIXT) announced it will participate in the DealFlow Discovery Conference to be held Jan. 28–29, 2026, in Atlantic City, N.J. The company said Chief Executive Officer Geordan Pursglove will conduct one-on-one meetings with investors during the conference as LIXTE continues advancing LB-100, its first-in-class inhibitor of protein phosphatase 2A, through clinical development. To view the full press release, visit https://ibn.fm/K3ih2 About Lixte Biotechnology Holdings, Inc. LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly…

TuesdayJan 20, 2026 9:00 am

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports Long-Term GelrinC(R) Imaging Data Demonstrating Native-Like Cartilage Regeneration

Regentis Biomaterials (NYSE American: RGNT) announced new long-term imaging data from its completed European clinical trial of GelrinC(R), showing regenerated cartilage with internal structural organization closely resembling healthy native hyaline cartilage. Published in the peer-reviewed journal Cartilage, the MRI-based analysis demonstrated progressive tissue maturation over 24 months, with repaired cartilage exhibiting layered architecture comparable to native tissue, supporting GelrinC(R)’s potential to deliver durable cartilage regeneration and long-term joint function. To view the full press release, visit https://ibn.fm/rEL4F About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance…

FridayJan 16, 2026 11:56 am

BioMedNewsBreaks — Diagnos Inc. (TSX Venture: ADK) (OTCQB: DGNOF) (FWB: 4D4A) Engages IBN for Corporate Communications and Awareness

Disseminated on behalf of Diagnos Inc. and may include paid advertising. Diagnos (TSX Venture: ADK) (OTCQB: DGNOF) (FWB: 4D4A), a pioneer in early detection of critical health issues using Artificial Intelligence-based technology, announced it has engaged Investor Brand Network (“IBN”) to provide corporate communication and awareness solutions. Under the one-year agreement effective Jan. 10, 2026, IBN will receive monthly compensation of US$6,400, payable in advance in cash from the Corporation’s funds. IBN will assist Diagnos in refining and strengthening its market awareness profile with the objective of maximizing shareholder value, is acting at arm’s length, and, together with its principals, holds no direct or indirect interest in the Corporation’s securities. The engagement remains subject to acceptance by…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) Highlights Board Appointments and AVERSA Fentanyl Milestones From Annual Meeting

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM)

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands U.S. Clinical Site Network for Phase III GelrinC(R) Trial

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Engages IBN for Corporate Communications Support

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Appoints Bryan Humbarger as Chief Commercial Officer

BioMedNewsBreaks — Oncotelic Therapeutics Inc.’s (OTLC) Deciparticle(TM) Platform Expands Possibilities in Immunology and Oncology

BioMedNewsBreaks — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) to Participate In DealFlow Discovery Conference

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports Long-Term GelrinC(R) Imaging Data Demonstrating Native-Like Cartilage Regeneration

BioMedNewsBreaks — Diagnos Inc. (TSX Venture: ADK) (OTCQB: DGNOF) (FWB: 4D4A) Engages IBN for Corporate Communications and Awareness

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search